The United States now has its first comprehensive cannabis patient research registry.
Headed up by Juva Life, a cannabis cultivator and life sciences innovator employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, WCG IRB (Puyallup, WA) -approved cannabis patient registry is now open and seeking applications from qualified patients. The patient registry is listed on clinicaltrials.gov.
Through the registry, Juva Life seeks to amass one of the world’s largest data sets of real world clinical evidence on the potential health benefits of cannabis, which will be used in clinical research programs in the future. As a recognized leader at the forefront of unlocking the therapeutic value of cannabis, Juva Life created the registry to help researchers and clinicians understand how cannabis may provide symptomatic relief for certain conditions and improve health outcomes for individuals.
“The data our research team intends to gather as part of this study is extremely valuable,” said Peter Beitsch, MD, a renowned oncologist, medical researcher and Principal investigator of Juva Life’s Clinical Registry, in Juva’s recent press release. “I’m involved because I have direct experience with patients who have been helped by cannabinoids. Of particular interest to me is the potential of cannabis as an alternative to opioid-based chronic pain relief, as well as ameliorating menopausal symptoms. This study will help further our understanding of the benefits of cannabinoids through real-world data gathering, thus enabling us to speak to the potential of cannabis in treating many chronic conditions.”
The study is open to patients over 21 years of age who have the following conditions or symptoms: chronic pain, anxiety, neuropathy, appetite issues, nausea, sleep issues, and menopausal symptoms. The goal of the registry is to collect data on cannabis formulations, chemical composition, dosing and utilization and the effectiveness of cannabis products in addressing these medical concerns. Additionally, the study will examine patients’ use of cannabis in conjunction with other prescription medication, including any discontinuation of the use of opioids or reduction in the use of opioids after initiation of cannabis-based medications.
“California has the largest cannabis market of adult users in the world, it makes sense that this kind of groundbreaking research is taking place in the Golden State, and I’m looking forward to seeing what we learn from this dataset of patients, and their experiences with cannabis and hemp products,” said Doug Chloupek, CEO and Founder of Juva. “But even more importantly, the Registry will offer a more robust understanding of how the cannabis plant interacts with the human body, especially when targeting certain medical conditions. This data will inform the future of pharmacological cannabis research and help us create healthy treatment options for patients in the future.”
The study is open to patients who live in California and wish to use products that contain tetrahydrocannabinol (THC) and patients nationwide who will use cannabidiol (CBD) products not containing more than 0.3% THC. Interested participants will be required to complete periodic confidential surveys about their symptoms, medication use and results and are also encouraged to download a simple journaling app to document daily the cannabis products they consumed, what effect they had on their specific symptoms and side effects should they occur.
The Juva Life cannabis patient registry is led by a team of leading doctors and clinicians. It is fully compliant with best medical practices for clinical research.Those adults interested in participating should contact Juva Life at juvaresearch.com/the-impact-study to check their eligibility and learn more about the study.
With its own cultivation, manufacturing, research, and retail operations, Juva Life is focused on ensuring quality control and efficient formulations throughout all stages of the cannabis supply chain. THC-containing products for the study will be provided through one of Juva’s licensed delivery services headquartered in Redwood City, CA. For patients interested in using CBD products, Juva has partnered with leading wellness brands such as San Benito Hemp Co in order to offer 50% discounted CBD products to patients nationwide.
At the conclusion of this multi-year study, Juva will have one of the largest data sets of its kind and be able to leverage the data in both its nutraceutical wellness, drug development and clinical programs. This real world observational data, will be presented to various regulatory bodies as further proof-of-concept and proof-of-safety of the potential therapeutic benefits of cannabis and cannabis-derived compounds.
Find out more at: https://juvalife.com.
Founder & Interim Editor of L.A. Cannabis News